Erudio Healtherudio.com
Sponsor
Johnson & Johnson trials: what clinicians said in public
HCP commentary reports on 11 clinical trials sponsored by Johnson & Johnson, including LIBERTAS, MonumenTAL-6, OrigAMI-5 and PRIMORDIUM. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 61 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Janssen Research & Development, LLC; Aragon Pharmaceuticals, Inc.; Cougar Biotechnology, Inc.; Janssen Pharmaceutica N.V., Belgium; Janssen Pharmaceutical K.K.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| GALAHAD NCT02854436 · Janssen Research & Development, LLC | metastatic castration-resistant prostate cancer with DNA-repair gene defects | Phase 2 | 272 | 15 | Standard | Nov 19, 2026 | Preview |
| EQUULEUS NCT01998971 · Janssen Research & Development, LLC | multiple myeloma | Phase 1 | 244 | 9 | Standard | Nov 18, 2026 | Preview |
| LIBERTAS NCT05884398 · Janssen Research & Development, LLC | metastatic castration-sensitive prostate cancer | Phase 3 | 898 | 55 | Deep | Nov 17, 2026 | Preview |
| OrigAMI-3 NCT06750094 · Janssen Research & Development, LLC | KRAS/NRAS and BRAF wild-type metastatic colorectal cancer | Phase 3 | 81 | 11 | Focused | Nov 16, 2026 | Preview |
| MonumenTAL-6 NCT06208150 · Janssen Research & Development, LLC | relapsed or refractory multiple myeloma | Phase 3 | 537 | 41 | Deep | Nov 16, 2026 | Preview |
| COU-AA-302 NCT00887198 · Janssen Research & Development, LLC | chemotherapy-naive metastatic castration-resistant prostate cancer | Phase 3 | 279 | 22 | Standard | Nov 15, 2026 | Preview |
| MoonRISe-3 NCT06919965 · Janssen Research & Development, LLC | high-risk non-muscle-invasive bladder cancer with susceptible FGFR alterations | Phase 3 | 76 | 13 | Focused | Nov 14, 2026 | Preview |
| OrigAMI-2 NCT06662786 · Janssen Research & Development, LLC | KRAS/NRAS and BRAF wild-type left-sided metastatic colorectal cancer | Phase 3 | 141 | 16 | Focused | Nov 1, 2026 | Preview |
| PRIMORDIUM NCT04557059 · Janssen Pharmaceutica N.V., Belgium | high-risk hormone-sensitive prostate cancer | Phase 3 | 312 | 19 | Deep | Nov 1, 2026 | Preview |
| OrigAMI-5 NCT07276399 · Janssen Research & Development, LLC | treatment-naïve recurrent/metastatic head and neck squamous cell carcinoma | Phase 3 | 449 | 32 | Deep | Nov 1, 2026 | Preview |
| OrigAMI-1 NCT05379595 · Janssen Research & Development, LLC | RAS/BRAF wild-type metastatic colorectal cancer | Phase 1/Phase 2 | 181 | 35 | Standard | Nov 1, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| CARTITUDE-4 NCT04181827 · Janssen Research & Development, LLC DeepView → | relapsed and lenalidomide-refractory multiple myeloma | Phase 3 | Deep | View | |||
| CARTITUDE-1 NCT03548207 · Janssen Research & Development, LLC DeepView → | relapsed or refractory multiple myeloma | Phase 1/Phase 2 | Deep | View | |||
| MajesTEC-3 NCT05083169 · Janssen Research & Development, LLC DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| PAPILLON NCT04538664 · Janssen Research & Development, LLC DeepView → | first-line EGFR exon 20 insertion-mutated advanced NSCLC | Phase 3 | Deep | View | |||
| AQUILA NCT03301220 · Janssen Research & Development, LLC DeepView → | high-risk smoldering multiple myeloma | Phase 3 | Deep | View | |||
| MAIA NCT02252172 · Janssen Research & Development, LLC DeepView → | transplant-ineligible newly diagnosed multiple myeloma | Phase 3 | Deep | View | |||
| PALOMA-3 NCT05388669 · Janssen Research & Development, LLC DeepView → | EGFR-mutated advanced or metastatic non-small cell lung cancer | Phase 3 | Deep | View | |||
| MajesTEC-9 NCT05572515 · Janssen Research & Development, LLC DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| CHRYSALIS-2 NCT04077463 · Janssen Research & Development, LLC DeepView → | advanced EGFR-mutant non-small cell lung cancer | Phase 1 | Deep | View | |||
| CHRYSALIS NCT02609776 · Janssen Research & Development, LLC DeepView → | advanced non-small cell lung cancer | Phase 1 | Deep | View | |||
| SunRISe-4 NCT04919512 · Janssen Research & Development, LLC DeepView → | muscle-invasive bladder cancer | Phase 2 | Deep | View | |||
| CARTITUDE-2 NCT04133636 · Janssen Research & Development, LLC DeepView → | multiple myeloma | Phase 2 | Deep | View | |||
| AURIGA NCT03901963 · Janssen Research & Development, LLC DeepView → | MRD-positive newly diagnosed multiple myeloma after transplant | Phase 3 | Deep | View | |||
| MonumenTAL-3 NCT05455320 · Janssen Research & Development, LLC DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| CARTITUDE-5 NCT04923893 · Janssen Research & Development, LLC DeepView → | Not given | Phase 3 | Deep | View | |||
| POLLUX NCT02076009 · Janssen Research & Development, LLC DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| RedirecTT-1 NCT04586426 · Janssen Research & Development, LLC DeepView → | relapsed or refractory multiple myeloma | Phase 1/Phase 2 | Deep | View | |||
| SunRISe-2 NCT04658862 · Janssen Research & Development, LLC DeepView → | muscle-invasive urothelial carcinoma of the bladder | Phase 3 | Deep | View | |||
| SunRISe-3 NCT05714202 · Janssen Research & Development, LLC DeepView → | BCG-naïve high-risk non-muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| ALCYONE NCT02195479 · Janssen Research & Development, LLC DeepView → | transplant-ineligible newly diagnosed multiple myeloma | Phase 3 | Deep | View | |||
| MARIPOSA NCT04487080 · Janssen Research & Development, LLC DeepView → | first-line EGFR-mutated advanced non-small cell lung cancer | Phase 3 | Deep | View | |||
| PALOMA NCT04606381 · Janssen Research & Development, LLC DeepView → | advanced solid malignancies | Phase 1 | Deep | View | |||
| OrigAMI-4 NCT06385080 · Janssen Research & Development, LLC DeepView → | head and neck squamous cell carcinoma | Phase 1/Phase 2 | Deep | View | |||
| SunRISe-5 NCT06211764 · Janssen Research & Development, LLC DeepView → | recurrent high-risk non-muscle-invasive bladder cancer after BCG | Phase 3 | Deep | View | |||
| MajesTEC-2 NCT04722146 · Janssen Research & Development, LLC DeepView → | multiple myeloma | Phase 1 | Deep | View | |||
| MajesTEC-7 NCT05552222 · Janssen Research & Development, LLC DeepView → | transplant-ineligible newly diagnosed multiple myeloma | Phase 3 | Deep | View | |||
| MoonRISe-1 NCT06319820 · Janssen Research & Development, LLC DeepView → | intermediate-risk non-muscle-invasive bladder cancer with susceptible FGFR alterations | Phase 3 | Deep | View | |||
| SunRISe-1 NCT04640623 · Janssen Research & Development, LLC DeepView → | BCG-unresponsive high-risk non-muscle-invasive bladder cancer | Phase 2 | Deep | View | |||
| CENTAURUS NCT02316106 · Janssen Research & Development, LLC DeepView → | intermediate/high-risk smoldering multiple myeloma | Phase 2 | Deep | View | |||
| RAGNAR NCT04083976 · Janssen Research & Development, LLC DeepView → | FGFR-altered advanced solid tumors | Phase 2 | Deep | View | |||
| MonumenTAL-2 NCT05050097 · Janssen Research & Development, LLC DeepView → | Not given | Phase 1 | Deep | View | |||
| MARIPOSA-2 NCT04988295 · Janssen Research & Development, LLC StandardView → | EGFR-mutated advanced non-small cell lung cancer after osimertinib | Phase 3 | Standard | View | |||
| COU-AA-301 NCT00638690 · Cougar Biotechnology, Inc. StandardView → | metastatic castration-resistant prostate cancer after docetaxel | Phase 3 | Standard | View | |||
| THOR NCT03390504 · Janssen Research & Development, LLC StandardView → | FGFR-altered advanced or metastatic urothelial carcinoma | Phase 3 | Standard | View | |||
| DELPHINUS NCT03384654 · Janssen Research & Development, LLC StandardView → | pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma | Phase 2 | Standard | View | |||
| COCOON NCT06120140 · Janssen Research & Development, LLC FocusedView → | first-line EGFR-mutated advanced NSCLC | Phase 2 | Focused | View | |||
| COPERNICUS NCT06667076 · Janssen Research & Development, LLC FocusedView → | EGFR-mutated locally advanced or metastatic NSCLC | Phase 2 | Focused | View | |||
| NCT02136134 NCT02136134 · Janssen Research & Development, LLC FocusedView → | Not given | Phase 3 | Focused | View | |||
| GRIFFIN NCT02874742 · Janssen Research & Development, LLC FocusedView → | transplant-eligible newly diagnosed multiple myeloma | Phase 2 | Focused | View | |||
| AMPLITUDE NCT04497844 · Janssen Research & Development, LLC FocusedView → | HRR-deficient metastatic castration-sensitive prostate cancer | Phase 3 | Focused | View | |||
| cAMeLot-2 NCT06852222 · Janssen Research & Development, LLC FocusedView → | Not given | Phase 3 | Focused | View | |||
| KLK2-comPAS NCT07164443 · Janssen Research & Development, LLC FocusedView → | late-line metastatic castration-resistant prostate cancer | Phase 3 | Focused | View | |||
| PROTEUS NCT03767244 · Janssen Research & Development, LLC FocusedView → | high-risk localized or locally advanced prostate cancer | Phase 3 | Focused | View | |||
| cAMeLot-1 NCT04811560 · Janssen Research & Development, LLC FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| NCT05316155 NCT05316155 · Janssen Research & Development, LLC FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| HLD-0915-ONC-101 NCT06800313 · Janssen Research & Development, LLC FocusedView → | metastatic prostate cancer | Phase 1/Phase 2 | Focused | View | |||
| TITAN NCT02489318 · Aragon Pharmaceuticals, Inc. FocusedView → | metastatic hormone-sensitive prostate cancer | Phase 3 | Focused | View | |||
| CEPHEUS NCT03652064 · Janssen Research & Development, LLC FocusedView → | transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma | Phase 3 | Focused | View | |||
| NCT04108195 NCT04108195 · Janssen Research & Development, LLC FocusedView → | Not given | Phase 1 | Focused | View | |||
| NCT04172675 NCT04172675 · Janssen Research & Development, LLC FocusedView → | Not given | Phase 2 | Focused | View | |||
| NCT05567185 NCT05567185 · Janssen Pharmaceutical K.K. FocusedView → | bladder cancer with FGFR mutations or fusions | Phase 1 | Focused | View | |||
| MajesTEC-1 NCT03145181 · Janssen Research & Development, LLC FocusedView → | relapsed or refractory multiple myeloma | Phase 1 | Focused | View | |||
| MAGNITUDE NCT03748641 · Janssen Research & Development, LLC FocusedView → | metastatic castration-resistant prostate cancer | Phase 3 | Focused | View | |||
| NCT01776840 NCT01776840 · Janssen Research & Development, LLC FocusedView → | newly diagnosed mantle cell lymphoma | Phase 3 | Focused | View | |||
| SPARTAN NCT01946204 · Aragon Pharmaceuticals, Inc. FocusedView → | Not given | Phase 3 | Focused | View | |||
| NCT02519452 NCT02519452 · Janssen Research & Development, LLC FocusedView → | relapsed or refractory multiple myeloma | Phase 1 | Focused | View | |||
| GLOW NCT03462719 · Janssen Research & Development, LLC FocusedView → | previously untreated chronic lymphocytic leukemia | Phase 3 | Focused | View | |||
| NCT04644770 NCT04644770 · Janssen Research & Development, LLC FocusedView → | Not given | Phase 1 | Focused | View | |||
| METalmark NCT05488314 · Janssen Research & Development, LLC FocusedView → | unresectable metastatic non-small cell lung cancer | Phase 1/Phase 2 | Focused | View | |||
| NCT06150157 NCT06150157 · Janssen Research & Development, LLC FocusedView → | Not given | Phase 1 | Focused | View | |||
| NCT07832292 NCT07832292 · Janssen Research & Development, LLC FocusedView → | metastatic androgen pathway modulation-resistant prostate cancer | Phase 2 | Focused | View | |||